Kapvay FDA Approval History
FDA Approved: Yes (First approved September 28, 2010)
Brand name: Kapvay
Generic name: clonidine hydrochloride
Dosage form: Extended-Release Tablets
Company: Shionogi Inc.
Treatment for: ADHD
Kapvay (clonidine hydrochloride) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Development timeline for Kapvay
| Date | Article |
|---|---|
| Oct 4, 2010 | Approval Shionogi Announces FDA Approval of Kapvay - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
